Cogent Biosciences, Inc. COGT R2KR3KPHARMA
Company Overview
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -65.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.99% |
| 1 Year: | -65.02% |
Stock Price Performance
| 1 Year: | +161.35% |
| 6 Months: | -13.36% |
| 3 Months: | -21.25% |
| 1 Month: | -0.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -2.0% CAGR over 5 years.
- Trading 26.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COGT Cogent Biosciences, Inc. R2KR3KPHARMA | 31.31 | -14.50 | $5.43B | 0.00% | -38.16% | -109.74% | -1.99% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83M | 2.08M | 2.33M | 2.12M | 2.22M | 1.67M | 2.04M | 3.81M | 3.05M | 3.14M | 1.02M | 15.29M | 7.03M | 528.00K | 312.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -6.07M | -6.03M | -7.17M | -6.88M | -6.99M | -9.44M | -10.58M | -9.00M | -11.84M | -10.54M | -12.04M | 2.24M | -6.14M | -7.40M | -57.20M | -12.80M | -17.29M | -19.82M | -31.42M | -35.85M | -36.82M | -43.24M | -47.09M | -59.58M | -62.40M | -64.39M | -75.41M | -74.93M | -75.58M | -83.36M | -103.61M |
| Net Income | -5.94M | -5.86M | -7.00M | -6.69M | -6.74M | -9.02M | -10.17M | -8.61M | -11.69M | -10.52M | -11.92M | 2.30M | -6.09M | -7.39M | -49.98M | -11.73M | -16.55M | -19.08M | -30.63M | -34.93M | -35.06M | -38.59M | -44.08M | -55.38M | -58.35M | -58.95M | -70.63M | -71.99M | -73.53M | -80.93M | -97.35M |
| Diluted EPS | - | - | - | - | -0.66 | -0.31 | -0.34 | -0.29 | -0.39 | -0.34 | -0.39 | 0.07 | - | - | - | - | -0.43 | -0.48 | -0.68 | -0.71 | -0.50 | -0.55 | -0.59 | -0.64 | -0.49 | -0.43 | -0.52 | -0.52 | -0.53 | -0.50 | -0.53 |
| R&D Expense | 6.95M | 7.14M | 8.18M | - | 8.14M | 9.13M | 10.25M | - | 12.40M | 10.62M | 10.34M | - | 9.50M | 5.13M | 5.00M | 8.21M | 12.39M | 14.80M | 25.47M | 29.48M | 29.94M | 36.04M | 38.87M | 50.13M | 52.70M | 54.29M | 63.61M | 63.03M | 62.20M | 68.99M | 75.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.36M | 9.73M | 22.50M | 7.87M | - | - | - | - | - |
| Operating Income | -26.15M | -36.01M | -32.18M | -82.20M | -75.55M | -147.84M | -208.13M | -275.94M | -333.36M |
| Net Income | -25.49M | -34.53M | -31.83M | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M | -328.94M |
| Diluted EPS | - | - | - | - | -1.87 | -1.73 | -1.94 | -1.94 | -2.16 |
| R&D Expense | 29.83M | 38.28M | 43.71M | 25.74M | 55.91M | 121.63M | 173.75M | 232.66M | 269.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 49.12M | 85.93M | 49.42M | 250.92M | 232.09M | 300.81M | 313.44M | 327.90M | 937.61M |
| Total Equity | -24.70M | -48.85M | 60.23M | 31.76M | 234.67M | 214.18M | 255.74M | 257.80M | 256.29M | 636.37M |
| Cash & Equivalents | - | 28.27M | 55.67M | 37.42M | 242.19M | 219.68M | 139.89M | 53.23M | 98.17M | 312.01M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 222.90M |
| Total Liabilities | - | 20.81M | 25.69M | 17.66M | 16.25M | 17.91M | 45.08M | 55.63M | 71.61M | 301.24M |
| Current Liabilities | - | 11.19M | 24.95M | 13.25M | 13.09M | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.84M | -32.49M | -41.51M | -35.85M | - | -118.64M | -153.62M | -207.79M | -264.44M |
| Investing Cash Flow | 13.59M | -10.53M | 23.16M | 8.42M | - | -124.72M | -97.82M | 38.28M | -399.53M |
| Financing Cash Flow | -729.00K | 70.35M | 108.00K | 232.20M | - | 163.56M | 163.54M | 214.45M | 878.23M |
| Capital Expenditure | -912.00K | -549.00K | -33.00K | - | - | -6.86M | -2.80M | -573.00K | -1.55M |
| Free Cash Flow | -26.75M | -33.04M | -41.55M | - | - | -125.50M | -156.42M | -208.36M | -266.00M |
| Net Change in Cash | - | - | - | - | - | -79.80M | -87.91M | 44.94M | 214.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -312.8% | -369.9% | -143.0% | -1,044.3% | - | - | - | - | - |
| Net Margin % | -304.9% | -354.8% | -141.5% | -950.4% | - | - | - | - | - |
| ROE % | 52.2% | -57.3% | -100.2% | -31.9% | -33.7% | -54.8% | -74.6% | -99.8% | -51.7% |
| ROCE % | -69.0% | -59.0% | -89.0% | -34.6% | -35.1% | -54.0% | -75.6% | -101.4% | -38.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.80% | 25.68M | $796.12M |
| 2 | Blackrock Inc. | 10.00% | 17.35M | $537.93M |
| 3 | Vanguard Portfolio Management LLC | 4.65% | 8.07M | $250.24M |
| 4 | Vanguard Capital Management LLC | 4.27% | 7.41M | $229.78M |
| 5 | State Street Corporation | 4.01% | 6.96M | $215.91M |
| 6 | Jupiter Topco LLC | 3.82% | 6.62M | $205.37M |
| 7 | Fairmount Funds Management LLC | 3.17% | 5.50M | $170.61M |
| 8 | Deerfield Management Company, L.P | 2.88% | 5.01M | $155.19M |
| 9 | TCG Crossover Management, LLC | 2.80% | 4.85M | $150.49M |
| 10 | Price (T.Rowe) Associates Inc | 2.68% | 4.65M | $144.23M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COGT
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1rWl80REc2cmJnOGVpLWRBNTl2Tm1FTjRKenkxMFJrelZrTnVhbVl5VE1oYm13SWRRM3VPZkxZSEpWMTNCQjcwYzJNak9ENHJJQmc?oc=5" target="_blank">Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote…
If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOSTZWVzctTjgyMHpSbEZkMk5zTU9hUWlQY0dMNnZ0V2RkdXpRZkxTMnE3ZFhBNXRvcWtNY2R3OHFBakU2OUZ3Z3JVSzZPeGsxYnNCMmxTejFFYlFVdG96QXVnQllYWi13bk1KUDVGcmtEQmhVQVIza1ZPRUFqdDRaSGtHSElMalhsVmxxMk…
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNZ21NeVY0VUh3MWs0cHQ2WFR2SmF6aTNMY0djVUR6U0RQaVVaUWg0eUZ6NkNFSGxGV3o5Wld3cXg5Z093VTNtWFBxVENhci1LZGItdlh6M0tJWlNXWDRqb05lRjAxRXRrRGEzSk5EYlp6cUI5YWl5dHlHc2NIUEhaOUxSVkpsSldIMEFrek…
COGT Nov 2026 31.000 put (COGT261120P00031000) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTFAxeWFkaUxJUUo4WXVwbV9JdDhkVENwTEp0X1FxbmVabTBfU0JCRlkzUTlfRlVqSklGMmpvY3pDc2VSUUdDYzJGblNqRlEzWC1VbVpUNEV3cnNDeWJYaEdJTnhNSnJJY29ndDNiVFNLNHA?oc=5" target="_blank">COGT Nov 2026 31…
COGT Nov 2026 38.000 call (COGT261120C00038000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9HTzBJMEItZ0hXVUY3LXhGMk1zWDZIeHo3TjhCMGlRei1CNDI2X3dScGdPYjB4Y1ptVl91Tld5SU1RWFJ2SFpEaUZzTm9sWnNST3lER0pYcFg4V2dKVi12MVpyZzlkQQ?oc=5" target="_blank">COGT Nov 2026 38.000 call (CO…
COGT Nov 2026 28.000 put (COGT261120P00028000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9jcmtOdlE4Ui1NN3RGM1pxMTU1Z1VKekZ3Y1o3bTNnMDltNVh0am0ybEZra3ZHUEl3NFZRM3pyNGt5UTZpY0U5VnFTX0NzR1NjclB0WDV3QVJVY3h0LXhPeHFPSkJKdw?oc=5" target="_blank">COGT Nov 2026 28.000 put (COG…
COGT — Frequently Asked Questions
What is the current share price of Cogent Biosciences, Inc. (COGT)?
As of 2026-10-22 16:30 PDT, Cogent Biosciences, Inc. (COGT) trades at $31.31 on NasdaqGS. Its 52-week range is $11.71 to $42.84.
What is the market capitalisation of COGT?
Cogent Biosciences, Inc. (COGT) has a market capitalisation of $5.43B on NasdaqGS.
What is the P/E ratio of COGT?
COGT trades at a trailing price-to-earnings (P/E) ratio of -14.50. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 11.38.
What is the return on equity (ROE) of COGT?
COGT has a return on equity (ROE) of -109.74%. Its return on capital employed (ROCE) is -38.16%.
Is COGT a good stock to buy?
This page provides a data-driven analysis of Cogent Biosciences, Inc. (COGT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.